References
- WHO, HIV/AIDS fact sheets, Available at https://www.who.int/news-room/fact-sheets/detail/hiv-aids
- R. Craigie, The molecular biology of HIV integrase, Future Virol. 7 (2012), pp. 679–686. doi:https://doi.org/10.2217/fvl.12.56.
- J.J. Kessl, S.B. Kutluay, D. Townsend, S. Rebensburg, A. Slaughter, R.C. Larue, N. Shkriabai, N. Bakouche, J.R. Fuchs, P.D. Bieniasz, and M. Kvaratskhelia, HIV-1 integrase binds the viral RNA genome and is essential during virion morphogenesis, Cell 166 (2016), pp. 1257–1268. doi:https://doi.org/10.1016/j.cell.2016.07.044.
- F. Christ and Z. Debyser, The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy, Virology 435 (2013), pp. 102–109. doi:https://doi.org/10.1016/j.virol.2012.09.033.
- U. Panwar and S.K. Singh, Structure-based virtual screening toward the discovery of novel inhibitors for impeding the protein-protein interaction between HIV-1 integrase and human lens epithelium-derived growth factor (LEDGF/p75), J. Biomol. Struct. Dyn. 36 (2018), pp. 3199–3217. doi:https://doi.org/10.1080/07391102.2017.1384400.
- K.K. Pandey and D.P. Grandgenett, HIV-1 integrase strand transfer inhibitors: Novel insights into their mechanism of action, Retrovirology (Auckl) 2 (2008), pp. 11–16. doi:https://doi.org/10.4137/rrt.s1081.
- K. Ramkumar, E. Serrao, S. Odde, and N. Neamati, HIV-1 integrase inhibitors: 2007-2008 update, Med. Res. Rev. 30 (2010), pp. 890–954. doi:https://doi.org/10.1002/med.20194.
- J.L. Elliott and S.B. Kutluay, Going beyond integration: The emerging role of HIV-1 integrase in virion morphogenesis, Viruses 12 (2020), pp. 1005. doi:https://doi.org/10.3390/v12091005.
- V. Summa, A. Petrocchi, F. Bonelli, B. Crescenzi, M. Donghi, M. Ferrara, F. Fiore, C. Gardelli, O.G. Paz, D.J. Hazuda, P. Jones, O. Kinzel, R. Laufer, E. Monteagudo, E. Muraglia, E. Nizi, F. Orvieto, P. Pace, G. Pescatore, R. Scarpelli, K. Stillmock, M.V. Witmer, and M. Rowley, Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection, Med. Chem. 51 (2008), pp. 5843–5855. doi:https://doi.org/10.1021/jm800245z.
- S.J. Smith, X.Z. Zhao, D.O. Passos, D. Lyumkis, T.R. Burke, and S.H. Hughes, HIV-1 integrase inhibitors that are active against drug-resistant integrase mutants, Antimicrob. Agents Chemother. 64 (2020), pp. e00611–00620. doi:https://doi.org/10.1128/AAC.00611-20.
- D. Komal, J. Khushboo, S. Aaftaab, S. Lakshmi, and A. Mallika, Targeting integrase enzyme: A therapeutic approach to combat HIV resistance, Mini Rev. Med. Chem. 20 (2020), pp. 219–238. doi:https://doi.org/10.2174/1389557519666191015124932.
- P. Gupta, P. Garg, and N. Roy, Identification of novel HIV-1 integrase inhibitors using shape-based screening, QSAR, and docking approach, Chem. Biol. Drug. Des. 79 (2012), pp. 835–849.
- P. Messiaen, A.M. Wensing, A. Fun, M. Nijhuis, N. Brusselaers, and L. Vandekerckhove, Clinical use of HIV integrase inhibitors: A systematic review and meta-analysis, PLoS One 8 (2013), pp. e52562. doi:https://doi.org/10.1371/journal.pone.0052562.
- Y. Goldgur, R. Craigie, G.H. Cohen, T. Fujiwara, Y. Yoshinaga, T. Fujishita, H. Sugimoto, T. Endo, H. Murai, and D.R. Davies, Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design, Proc. Natl. Acad. Sci. USA 96 (1999), pp. 13040–13043. doi:https://doi.org/10.1073/pnas.96.23.13040.
- D. Mendez, A. Gaulton, A.P. Bento, J. Chambers, M. De Veij, E. Félix, M.P. Magariños, J.F. Mosquera, P. Mutowo, M. Nowotka, M. Gordillo-Marañón, F. Hunter, L. Junco, G. Mugumbate, M. Rodriguez-Lopez, F. Atkinson, N. Bosc, C.J. Radoux, A.S. Cabrera, A. Hersey, and A.R. Leach, ChEMBL: Towards direct deposition of bioassay data, Nucleic Acids Res. 47 (2019), pp. D930–D940. doi:https://doi.org/10.1093/nar/gky1075.
- Danishuddin and A.U. Khan, Descriptors and their selection methods in QSAR analysis: Paradigm for drug design, Drug Discov. Today 21 (2016), pp. 1291–1302. doi:https://doi.org/10.1016/j.drudis.2016.06.013.
- A.G. Mercader, P.R. Duchowicz, F.M. Fernández, and E.A. Castro, Modified and enhanced replacement method for the selection of molecular descriptors in QSAR and QSPR theories, Chemom. Intell. Lab. Syst. 92 (2008), pp. 138–144. doi:https://doi.org/10.1016/j.chemolab.2008.02.005.
- C.W. Yap, PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints, J. Comput. Chem. 32 (2011), pp. 1466–1474. doi:https://doi.org/10.1002/jcc.21707.
- M.B. Kursa, A. Jankowski, and W.R. Rudnicki, Boruta- A system for feature selection, Fundam. Informat. 101 (2010), pp. 271–285. doi:https://doi.org/10.3233/FI-2010-288.
- TensorFlow lite, software available at https://www.tensorflow.org/lite/guide. (Accessed November 14, 2021)
- M.K. Warmuth, J. Liao, G. Rätsch, M. Mathieson, S. Putta, and C. Lemmen, Active learning with support vector machines in the drug discovery process, J. Chem. Inf. Comput. Sci. 43 (2003), pp. 667–673. doi:https://doi.org/10.1021/ci025620t.
- L. Breiman, Random forests, Mach. Learn 45 (2001), pp. 5–32. doi:https://doi.org/10.1023/A:1010933404324.
- T. Chen and C. Guestrin, XGBoost: A scalable tree boosting system, Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, ACM, New York, NY, USA.
- M. Grandini, E. Bagli, and G. Visani, Metrics for multi-class classification: An overview, preprint (2020), submitted for publication. Avaialble at https://doi.org/http://doi.org/10.48550/arXiv.2008.0575. (Accessed November 19, 2021)
- C. Drummond and R.C. Holte, Cost curves: An improved method for visualizing classifier performance, Mach. Learn. 65 (2006), pp. 95–130. doi:https://doi.org/10.1007/s10994-006-8199-5.
- A. El-Ansary, G. Bjørklund, S. Chirumbolo, and O.M. Alnakhli, Predictive value of selected biomarkers related to metabolism and oxidative stress in children with autism spectrum disorder, Metab. Brain Dis. 32 (2017), pp. 1209–1221. doi:https://doi.org/10.1007/s11011-017-0029-x.
- T.I.M. Rakhimbekova, R.I. Nugmanov, T.R. Gimadiev, I.I. Baskin, and A. Varnek, Comprehensive analysis of applicability domains of QSPR models for chemical reactions, Int. J. Mol. Sci. 21 (2020), pp. 5542. doi:https://doi.org/10.3390/ijms21155542.
- S. Sushko, R. Novotarskyi, A.K. Körner, A. Pandey, J. Cherkasov, P. Li, K. Gramatica, T. Hansen, K.R. Schroeter, L. Müller, H. Xi, X. Liu, T. Yao, F. Öberg, P. Hormozdiari, C. Dao, R. Sahinalp, P. Todeschini, A. Polishchuk, V. Artemenko, T.M. Kuzmin, D.M. Martin, D. Young, E. Fourches, A. Muratov, I. Tropsha, D. Baskin, G. Horvath, C. Marcou, A. Muller, V.V. Varnek, Prokopenko, and I.V. Tetko, Applicability domains for classification problems: Benchmarking of distance to models for ames mutagenicity set, J. Chem. Inf. Model. 50 (2010), pp. 2094–2111. doi:https://doi.org/10.1021/ci100253r.
- M.L. Verdonk, J.C. Cole, M.J. Hartshorn, C.W. Murray, and R.D. Taylor, Improved protein-ligand docking using GOLD, Proteins 52 (2003), pp. 609–623. doi:https://doi.org/10.1002/prot.10465.
- M.J. Abraham, T. Murtola, R. Schulz, S. Páll, J.C. Smith, B. Hess, and E. Lindah, Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers, SoftwareX 1-2 (2015), pp. 19–25. doi:https://doi.org/10.1016/j.softx.2015.06.001.
- X. Zhu, P.E.M. Lopes, and M. A.d, Recent developments and applications of the CHARMM force fields, Wiley Interdiscip. Rev. Comput. Mol. Sci. 2 (2012), pp. 167–185. doi:https://doi.org/10.1002/wcms.74.
- M. Parrinello and A. Rahman, Polymorphic transitions in single crystals: A new molecular dynamics method, J. Appl. Phys. 52 (1981), pp. 7182–7190. doi:https://doi.org/10.1063/1.328693.
- H.B. Hess, H.J.C. Berendsen, and J.G.E.M. Fraaije, LINCS: A linear constraint solver for molecular simulations, J. Comput. Chem. 18 (1997), pp. 1463–1472. doi:https://doi.org/10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H.
- M. Métifiot, C. Marchand, and Y. Pommier, HIV integrase inhibitors: 20-year landmark and challenges, Adv. Pharmacol. 67 (2013), pp. 75–105.
- L. Saiz-Urra, M.P. Gonzalez, Y. Fall, and G. Gomez, Quantitative structure–activity relationship studies of HIV-1 integrase inhibition. 1. GETAWAY descriptors, Eur. J. Med. Chem. 42 (2007), pp. 64–70. doi:https://doi.org/10.1016/j.ejmech.2006.08.005.
- M. Iyer and A.J. Hopfinger, Treating chemical diversity in QSAR analysis: Modeling diverse HIV-1 integrase inhibitors using 4D fingerprints, J. Chem. Inf. Model. 475 (2007), pp. 1945–1960. doi:https://doi.org/10.1021/ci700153g.
- D.K. Dhaked, J. Verma, A. Saran, and E.C. Coutinho, Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRI), J. Mol. Model. 15 (2009), pp. 233–245. doi:https://doi.org/10.1007/s00894-008-0399-4.
- K. Hajian-Tilaki, Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation, Casp. J. Intern. Med. 4 (2013), pp. 627–635.
- A. Qureshi, A. Rajput, G. Kaur, and M. Kumar, HIVprotI: An integrated web based platform for prediction and design of HIV proteins inhibitors, J. Cheminform. 10 (2018), pp. 12. doi:https://doi.org/10.1186/s13321-018-0266-y.
- A. Cai, P. Guo, Y. Zhou, J. Zhou, Q. Wang, F. Zhang, J. Fang, and F. Cheng, Deep learning-based prediction of drug-induced cardiotoxicity, J. Chem. Inf. Model. 59 (2019), pp. 1073–1084. doi:https://doi.org/10.1021/acs.jcim.8b00769.
- L.H. Mervin, A.M. Afzal, G. Drakakis, R. Lewis, O. Engkvist, and A. Bender, Target prediction utilising negative bioactivity data covering large chemical space, J. Cheminform. 7 (2015), pp. 51. doi:https://doi.org/10.1186/s13321-015-0098-y.
- I.L. Ruiz and G.-N. M.a, Study of the applicability domain of the QSAR classification models by means of the rivality and modelability indexes, Molecules 23 (2018), pp. 2756. doi:https://doi.org/10.3390/molecules23112756.
- J. Jaworska, N. Nikolova-Jeliazkova, and T. Aldenberg, QSAR applicability domain estimation by projection of the training set in descriptor space: A review, Altern. Lab. Anim. 33 (2005), pp. 445–459. doi:https://doi.org/10.1177/026119290503300508.
- H. Yuan and A.L. Parrill, QSAR studies of HIV-1 integrase inhibition, Bioorg. Med. Chem. 10 (2002), pp. 4169–4183. doi:https://doi.org/10.1016/S0968-0896(02)00332-2.
- K.K. Reddy, S.K. Singh, S.K. Tripathi, and C. Selvaraj, Identification of potential HIV-1 integrase strand transfer inhibitors: In silico virtual screening and QM/MM docking studies, SAR QSAR Environ. Res. 24 (2013), pp. 581–595. doi:https://doi.org/10.1080/1062936X.2013.772919.
- M.S. Han, C. Wang, C. Wang, C. Wang, and C. Wang, Structure- activity relationship and binding mode studies for a series of diketo-acids as HIV integrase inhibitors by 3DQSAR, molecular docking and molecular dynamics simulations, RSC Adv. 6 (2016), pp. 27594–27606. doi:https://doi.org/10.1039/C6RA00713A.
- C.N. Alves, S. Marti, R. Castillo, J. Andres, V. Moliner, I. Tunon, and E.A. Silla, A quantum mechanic/molecular mechanic study of the wild-type and N155S mutant HIV-1 integrase complexed with diketo acid, Biophysics J. 94 (2008), pp. 2443–2451. doi:https://doi.org/10.1529/biophysj.107.107623.